Dyslipidemia, characterized by abnormal lipid levels in the bloodstream, is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD). Understanding and managing this condition effectively is paramount to reducing associated morbidity and mortality.
Dyslipidemia can be primary, stemming from genetic factors, or secondary, resulting from lifestyle or other underlying conditions. It involves an imbalance in the levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides, leading to the development of atherosclerotic plaques.
Patients with dyslipidemia are often asymptomatic until the onset of complications such as ASCVD. Diagnosis is primarily based on lipid profile testing, which includes total cholesterol, LDL-C, HDL-C, and triglycerides.
Management involves lifestyle modification and pharmacotherapy. Lifestyle changes include a healthy diet, regular exercise, and smoking cessation. Pharmacological interventions are based on the type and severity of dyslipidemia, with statins being the first-line therapy for elevated LDL-C. Other agents like fibrates, niacin, and ezetimibe may be used as adjunctive therapy or in patients intolerant to statins.
Regular monitoring of lipid levels and therapeutic response is crucial to ensure treatment efficacy and to modify the management plan if necessary. The frequency of monitoring depends on the initial lipid levels, the patient's risk factors, and the response to therapy.
Understanding and effectively managing dyslipidemia is vital for reducing the risk of ASCVD. A comprehensive approach involving accurate diagnosis, appropriate treatment, and regular monitoring can help achieve optimal lipid levels and improve patient outcomes.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation